You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

CLINICAL TRIALS PROFILE FOR TISSEEL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TISSEEL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00028951 ↗ Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed National Cancer Institute (NCI) Phase 3 2003-01-01 RATIONALE: Fibrin sealant may decrease lymphedema following surgery to remove lymph nodes in the groin by helping to seal the lymphatic vessels. It is not yet known if fibrin sealant is effective in decreasing lymphedema following surgery to remove lymph nodes. PURPOSE: Randomized phase III trial to determine the effectiveness of fibrin sealant in reducing lymphedema following surgical removal of lymph nodes in patients who have cancer of the vulva.
NCT00028951 ↗ Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed Gynecologic Oncology Group Phase 3 2003-01-01 RATIONALE: Fibrin sealant may decrease lymphedema following surgery to remove lymph nodes in the groin by helping to seal the lymphatic vessels. It is not yet known if fibrin sealant is effective in decreasing lymphedema following surgery to remove lymph nodes. PURPOSE: Randomized phase III trial to determine the effectiveness of fibrin sealant in reducing lymphedema following surgical removal of lymph nodes in patients who have cancer of the vulva.
NCT00155402 ↗ The Application of Fibrin Glue in Ocular Surface Diseases Withdrawn National Taiwan University Hospital Phase 1 2005-04-01 This clinical trial tries to use tissue fibrin glues (Tisseel) to treat various ocular surface diseases or surgeries, which includes pterygium surgery, corneal melting/perforation, Gunderson's flap, conjunctival laceration, and muscle/clinical/filtering surgery.
NCT00161733 ↗ Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery Completed Baxter Healthcare Corporation Phase 3 2002-09-01 The objective of this study is to demonstrate equivalent hemostatic efficacy and safety between FS VH S/D and TISSEEL VH fibrin sealant in subjects undergoing cardiac surgery requiring cardiopulmonary bypass. If bleeding is still present after conventional surgical methods to achieve hemostasis have been applied FS VH S/D or Tisseel VH are applied. Achievement of hemostasis within 5 minutes is compared between the study groups.
NCT00504582 ↗ Fibrin Melanoma Axillary Node Study in Patients With Melanoma Completed M.D. Anderson Cancer Center N/A 2002-05-01 Primary Objective: - To determine whether the use of a fibrin sealant applied to axillary soft tissues following node dissection can result in earlier drain removal. Secondary Objectives: - To determine the postoperative morbidity rate using fibrin sealant following axillary node dissection. - To assess patient-valuation of outcome by performing a cost-benefit analysis using a willingness-to-pay model. - To determine if serum levels, lymphatic fluids level, or cutaneous expression of vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) correlates with nodal tumor burden or development of lymphedema in patients with melanoma.
NCT00506311 ↗ Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients Completed Bayer N/A 2003-02-01 Primary Objective: 1. To determine whether the use of a fibrin sealant applied to superficial groin soft tissues following node dissection can result in decreased cumulative postoperative drainage, earlier drain removal, and lower incidence of seroma. Secondary Objectives: 1. To determine the postoperative morbidity rate using fibrin sealant following superficial groin dissection. 2. To assess patient-valuation of outcome by performing a cost-benefit analysis using a willingness-to-pay model. 3. To determine if serum levels, lymphatic fluids level, or cutaneous expression of vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) correlates with nodal tumor burden or development of lymphedema in patients with melanoma.
NCT00506311 ↗ Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients Completed M.D. Anderson Cancer Center N/A 2003-02-01 Primary Objective: 1. To determine whether the use of a fibrin sealant applied to superficial groin soft tissues following node dissection can result in decreased cumulative postoperative drainage, earlier drain removal, and lower incidence of seroma. Secondary Objectives: 1. To determine the postoperative morbidity rate using fibrin sealant following superficial groin dissection. 2. To assess patient-valuation of outcome by performing a cost-benefit analysis using a willingness-to-pay model. 3. To determine if serum levels, lymphatic fluids level, or cutaneous expression of vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3) correlates with nodal tumor burden or development of lymphedema in patients with melanoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TISSEEL

Condition Name

Condition Name for TISSEEL
Intervention Trials
Melanoma 2
Cardiopulmonary Bypass 1
Intra-abdominal Infection 1
Vaginal Bleeding 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TISSEEL
Intervention Trials
Cerebrospinal Fluid Rhinorrhea 2
Melanoma 2
Hernia 2
Cerebrospinal Fluid Leak 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TISSEEL

Trials by Country

Trials by Country for TISSEEL
Location Trials
United States 56
Spain 2
Turkey 2
Germany 2
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for TISSEEL
Location Trials
Texas 5
Minnesota 4
Ohio 3
North Carolina 3
Michigan 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TISSEEL

Clinical Trial Phase

Clinical Trial Phase for TISSEEL
Clinical Trial Phase Trials
Phase 4 4
Phase 3 5
Phase 2 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TISSEEL
Clinical Trial Phase Trials
Completed 10
Recruiting 3
Withdrawn 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TISSEEL

Sponsor Name

Sponsor Name for TISSEEL
Sponsor Trials
Baxter Healthcare Corporation 4
M.D. Anderson Cancer Center 2
Hobart Harris 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TISSEEL
Sponsor Trials
Other 19
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.